NXP900
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma
Trial Timeline
Oct 26, 2023 → Jul 1, 2027
NCT ID
NCT05873686About NXP900
NXP900 is a phase 1 stage product being developed by Nuvectis Pharma for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05873686. Target conditions include Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05873686 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor